Simultaneous HPLC-APCI-MS/MS quantification of endogenous cannabinoids and glucocorticoids in hair

Mwanza, Christopher; Zheng, Chen; Zhang, Quan; Chen, Shenghuo; Wang, Weiwen; Deng, Huihua

doi:10.1016/j.jchromb.2016.06.002

Cited by 29 publications

(8 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature search identified 1017 unique citation titles of which a total of 120 studies 5,13,14,16,19,30,33–146 comprising 146 separate cohorts were included (Figure 1). This corresponds to a total of 34,342 included participants of which 15,698 (46%) were sampled from general population‐based studies (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Cross‐sectional relation of long‐term glucocorticoids in hair with anthropometric measurements and their possible determinants: A systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

Summary Background Long‐term glucocorticoids (HairGC) measured in scalp hair have been associated with body mass index (BMI), waist circumference (WC), and waist‐hip‐ratio (WHR) in several cross‐sectional studies. We aimed to investigate the magnitude, strength, and clinical relevance of these relations across all ages. Methods We performed a systematic review and meta‐analysis (PROSPERO registration CRD42020205187) searching for articles relating HairGC to measures of obesity. Main outcomes were bivariate correlation coefficients and unadjusted simple linear regression coefficients relating hair cortisol (HairF) and hair cortisone (HairE) to BMI, WC, and WHR. Results We included k = 146 cohorts (n = 34,342 individuals). HairGC were positively related to all anthropometric measurements. The strongest correlation and largest effect size were seen for HairE‐WC: pooled correlation 0.18 (95%CI 0.11–0.24; k = 7; n = 3,158; I2 = 45.7%) and pooled regression coefficient 11.0 cm increase in WC per point increase in 10‐log‐transformed HairE (pg/mg) on liquid‐chromatography‐(tandem) mass spectrometry (LC–MS) (95%CI 10.1–11.9 cm; k = 6; n = 3,102). Pooled correlation for HairF‐BMI was 0.10 (95%CI 0.08–0.13; k = 122; n = 26,527; I2 = 51.2%) and pooled regression coefficient 0.049 kg/m2 per point increase in 10‐log‐transformed HairF (pg/mg) on LC–MS (95%CI 0.045–0.054 kg/m2; k = 26; n = 11,635). Discussion There is a consistent positive association between HairGC and BMI, WC, and WHR, most prominently and clinically relevant for HairE‐WC. These findings overall suggest an altered setpoint of the hypothalamic–pituitary–adrenal axis with increasing central adiposity.

show abstract

Section: Resultsmentioning

confidence: 99%

Cross‐sectional relation of long‐term glucocorticoids in hair with anthropometric measurements and their possible determinants: A systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The present study showed LOD and LOQ matched or lower than those in previous publications for cortisol, cortisone, MAM, MDMA, ketamine, morphine and 6-AM. For instance, Chen et al [ 17 ] and Christopher et al [ 29 ] reported LODs at 2 and 0.5 pg/mg for cortisol and cortisone. Lendoiro et al [ 26 ] reported LODs at 2 pg/mg for ketamine, MAM, MDMA and 6-AM, and at 5 pg/mg for morphine.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous Determination of Cortisol, Cortisone, and Multiple Illicit Drugs in Hair among Female Drug Addicts with LC-MS/MS

Duan

Yang

et al. 2021

Molecules

Self Cite

View full text Add to dashboard Cite

Long-term dependence of illicit drugs impairs the function of the hypothalamic-pituitary-adrenal (HPA) axis, which regulates the secretion of endogenous steroids, cortisol, and cortisone. Thus, the present study aimed to develop a sensitive method for simultaneous determination of the multiple illicit drugs and two steroids in hair to monitor the status of illicit drug exposure and the physiological and psychological health of drug addicts. The target analytes were extracted from hair by incubation with 1 mL methanol for 24 h at 40 °C and then determined with LC-APCI+-MS/MS. The validated method showed acceptable linearity (R2 > 0.99) in the range of 1.25–250 pg/mg for cortisol and cortisone, 2.5–125 pg/mg for heroin, 2.5–1250 pg/mg for ketamine, 2.5–5000 pg/mg for methamphetamine (MAM), 2.5–250 pg/mg for 3, 4-methylenedioxymethamphetamine (MDMA), morphine, and 6-monoacetylmorphine (6-AM). Limits of quantification were 1.6, 1.2, 1.6, 1.0, 1.4, 0.3, 2.1, and 1.2 pg/mg for cortisol, cortisone, heroin, ketamine, MAM, MDMA, morphine, and 6-AM, respectively. Method recoveries were from 90–115% for all analytes. Inter-day and intra-day coefficients of variation were within 10%. Finally, this method was successfully applied to detect the aforementioned analytes in hair among female drug addicts who self-reported to be MAM abuser, heroin abuser, ketamine abuser, and abuser of mixture drugs of MAM and heroin. MAM abusers with current MAM use showed significantly higher concentrations of cortisol, MAM, and MDMA than controls with drug withdrawal.

show abstract

“…The expression and/or localisation of functional CB 2 protein has also been reported for mast cells, modulating their initial activation, or downregulating their activity post their initial activation, an activity change which can in turn provoke an anti-inflammatory response [75]. Anandamide and 2-AG, as well as their metabolic enzymes, are detectable in blood [76,77], hair [78][79][80], saliva [81][82][83], breast milk [84,85], and reproductive fluids [84,86]. Compounded with the peripheral anti-inflammatory response, CB 2 receptor agonists can mediate peripheral antinociception without the psychotropic CNS effects associated with phytocannabinoid CB 1 receptor binding [87,88].…”

Section: The Endocannabinoid System and Its Associated Molecular Targmentioning

confidence: 95%

Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

Oultram

Pegler

Bowser³

et al. 2021

Biomedicines

View full text Add to dashboard Cite

Cannabis sativa (Cannabis) is one of the world’s most well-known, yet maligned plant species. However, significant recent research is starting to unveil the potential of Cannabis to produce secondary compounds that may offer a suite of medical benefits, elevating this unique plant species from its illicit narcotic status into a genuine biopharmaceutical. This review summarises the lengthy history of Cannabis and details the molecular pathways that underpin the production of key secondary metabolites that may confer medical efficacy. We also provide an up-to-date summary of the molecular targets and potential of the relatively unknown minor compounds offered by the Cannabis plant. Furthermore, we detail the recent advances in plant science, as well as synthetic biology, and the pharmacology surrounding Cannabis. Given the relative infancy of Cannabis research, we go on to highlight the parallels to previous research conducted in another medically relevant and versatile plant, Papaver somniferum (opium poppy), as an indicator of the possible future direction of Cannabis plant biology. Overall, this review highlights the future directions of cannabis research outside of the medical biology aspects of its well-characterised constituents and explores additional avenues for the potential improvement of the medical potential of the Cannabis plant.

show abstract

Simultaneous HPLC-APCI-MS/MS quantification of endogenous cannabinoids and glucocorticoids in hair

Cited by 29 publications

References 67 publications

Cross‐sectional relation of long‐term glucocorticoids in hair with anthropometric measurements and their possible determinants: A systematic review and meta‐analysis

Cross‐sectional relation of long‐term glucocorticoids in hair with anthropometric measurements and their possible determinants: A systematic review and meta‐analysis

Simultaneous Determination of Cortisol, Cortisone, and Multiple Illicit Drugs in Hair among Female Drug Addicts with LC-MS/MS

Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

Contact Info

Product

Resources

About